These target-directed therapeutic approaches are in line with preclinical studies demonstrating a beneficial effect of CSF1-R inhibitor-induced microglia depletion, e.g., in Alzheimer disease models and after traumatic brain injury (22, 23). This evidence concerns the gene CSF1R and early-onset autosomal dominant Alzheimer disease.